YESCARTAHCP.COM: Keyword Density Checker

Total words: 6625 | 2-word phrases: 1679 | 3-word phrases: 2038 | 4-word phrases: 2194

PAGE INFO

Title	Try to keep the title under 60 characters (88 characters) YESCARTA® (axicabtagene ciloleucel) for Treatment of 2L R/R Large B-Cell Lymphoma \| HCP
Description	Try to keep the meta description between 50 - 160 characters (170 characters) YESCARTA® (axicabtagene ciloleucel) HCP website for 2L relapsed/refractory (R/R) large B-cell lymphoma (LBCL). See full Prescribing Information, including BOXED WARNING.
Keywords	Meta keywords are not recommended anymore (0 characters)
H1	No H1 tag on the page (0 characters)

#	Keyword	Frequency	Density
1	large bcell lymphoma	10	0.49%
2	median time to	10	0.49%
3	patients with lbcl	10	0.49%
4	time to onset	9	0.44%
5	of patients with	8	0.39%
6	of crs was	8	0.39%
7	with lbcl in	7	0.34%
8	kite pharma inc	7	0.34%
9	data on file	7	0.34%
10	the median time	7	0.34%
11	grade 3 in	6	0.29%
12	to onset of	6	0.29%
13	median duration was	5	0.25%
14	patients with inhl	5	0.25%
15	onset of crs	5	0.25%
16	patients with nhl	5	0.25%
17	in patients with	5	0.25%
18	lbcl in zuma1	4	0.20%
19	and the median	4	0.20%
20	the median duration	4	0.20%
21	neurologic toxicities occurred	4	0.20%
22	crs occurred in	4	0.20%
23	was 6 days	4	0.20%
24	grade 3 crs	4	0.20%
25	adult patients with	4	0.20%
26	days and the	4	0.20%
27	including ≥ grade	4	0.20%
28	6 days range	4	0.20%
29	≥ grade 3	4	0.20%
30	neurologic toxicities in	4	0.20%

#	Keyword	Frequency	Density
1	median time to onset	9	0.41%
2	the median time to	7	0.32%
3	time to onset of	6	0.27%
4	patients with lbcl in	6	0.27%
5	onset of crs was	5	0.23%
6	including ≥ grade 3	4	0.18%
7	was 6 days range	4	0.18%
8	to onset of crs	4	0.18%
9	with lbcl in zuma1	4	0.18%
10	with lbcl in zuma7	3	0.14%
11	≥ grade 3 in	3	0.14%
12	neurologic toxicities occurred in	3	0.14%
13	with large bcell lymphoma	3	0.14%
14	genetically modified autologous t	3	0.14%
15	patients with large bcell	3	0.14%
16	of patients with nhl	3	0.14%
17	in patients with lbcl	3	0.14%
18	was 4 days range	3	0.14%
19	days for patients with	3	0.14%
20	patients for signs and	3	0.14%
21	days and the median	3	0.14%
22	lymphoma n engl j	3	0.14%
23	the median duration was	3	0.14%
24	crs and neurologic toxicities	3	0.14%
25	and the median duration	3	0.14%
26	large bcell lymphoma n	3	0.14%
27	in patients receiving yescarta	3	0.14%
28	n engl j med	3	0.14%
29	bcell lymphoma n engl	3	0.14%
30	10 in all patients	2	0.09%
31	≥ 10 in all	2	0.09%
32	certified healthcare facility and	2	0.09%
33	mj et al survival	2	0.09%
34	all patients combined included	2	0.09%
35	healthcare facility and for	2	0.09%
36	for 4 weeks thereafter	2	0.09%
37	facility and for 4	2	0.09%
38	and for 4 weeks	2	0.09%
39	et al survival with	2	0.09%
40	in all patients combined	2	0.09%

#	URL	Whois	Check
1	https://www.YescartaTecartusREMS.com	Whois	YescartaTecartusREMS.com
2	https://www.gilead.com/-/media/files/pdfs/medicines/oncology/yescarta/yescarta-pi.pdf	Whois	gilead.com
3	https://www.yescarta.com/	Whois	yescarta.com